SWK Holdings Corp

SWK — Q1 2025 Earnings Presentation

31 slides from SWK's earnings presentation, May 15, 2025

  1. Slide 1: Collaborative Approach to Life Science Financing: Shareholder Presentation 1Q25

    1 Collaborative Approach to Life Science Financing Shareholder Presentation 1Q25 | May 2025

  2. Slide 2: Forward-looking and Cautionary Statements

    2 Forward-looking and Cautionary Statements Statements in this presentation that are not strictly historical, and any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward- looking" statements within the meaning of the federal securiti

  3. Slide 3: SWK Holdings - Overview

    SWK Holdings - Overview 3 Underserved, High- Need Market Demonstrated Success, Attractive Returns Focus on Shareholder Returns Custom financing solutions for commercial-stage healthcare companies and royalty owners • SWK targets $5M to $25M financings, a market niche that is less competitive and gen

  4. Slide 4: Slide JT0 C:\Users\JD Tamas\SWK Holdings Corporation\SWK - DataCommon\Financial Reporting\Portfolio Data JD Tamas, 20…

    Slide 3 JT0 C:\Users\JD Tamas\SWK Holdings Corporation\SWK - DataCommon\Financial Reporting\Portfolio Data JD Tamas, 2024-03-07T18:39:29.345 JT0 0 Includes syndicated volume and is before OID (i.e., larger figure) JD Tamas, 2024-08-13T14:36:02.703 JT1 C:\Users\JD Tamas\SWK Holdings Corporation\SWK -

  5. Slide 5: Operating Segments

    4 Operating Segments LIFE SCIENCE SPECIALTY FINANCE MOD3 Pharma (fka Enteris Biopharma) • Senior secured term loans • Royalties • Synthetic royalties • Hybrid structures • CDMO and CMO services • Orally inhaled and nasal drug delivery solutions • Strategic partnership SWK operates through two segmen

  6. Slide 6: Why Life Science Finance?

    5 Why Life Science Finance? Tap into underlying demand that is pervasive, growing, and minimally correlated with economic cycles • Healthcare spend is large and increasing, representing 20% of U.S. GDP; forecast to grow at a 5% CAGR through 20301 • Sector has demonstrated durability as S&P 500 sales

  7. Slide 7: Value Creation Strategy

    6 Value Creation Strategy SWK believes this strategy will continue to achieve a 10%+ book value per share CAGR Deploy balance sheet capital into secured financing portfolio • SWK has established reputation as a go-to capital provider in our market segment • Majority of financings structured with war

  8. Slide 8: Book Value Components

    7 Book Value Components Tangible Finance Book Value / Share = $21.73 • Excludes value of deferred tax asset and MOD3 PP&E • SWK’s targets 10%+ CAGR of tangible finance book value / share Plus: MOD3 Pharma Net Book Value / Share = $0.40 • Strategic partner has option through January 1, 2026 to purcha

  9. Slide 9: Corporate Milestones

    8 Corporate Milestones 2019  17th partner exit realized, bringing the weighted avg. IRR on all exits to 20%  Acquired MOD3 Pharma  Ended year with $178.7M investment assets 2020  Uplisted to Nasdaq and added to Russell 2000 Index  Ended year with $212.5M investment assets 2022  Reconstituted B

  10. Slide 10: Slide JT0 Note this is net of GR basket and includes marketable investments and

    Slide 8 JT0 Note this is net of GR basket and includes marketable investments and warrants from BS JD Tamas, 2024-03-07T21:42:55.686

  11. Slide 11: First Quarter 2025 Recap

    First Quarter 2025 Recap 9CONFIDENTIAL CORPORATE UPDATES FINANCE RECEIVABLES UPDATES • In 1Q25, SWK repurchased 52K shares of stock for a total cost of $867K • During 2025 monetized performing royalty portfolio for $51.3M • In May, paid $49.1M ($4.00 per share) dividend • As of 1Q25, non-GAAP tangib

  12. Slide 12: Finance Portfolio Overview: 1Q25 Pro Forma for Royalty Monetization

    10 Finance Portfolio Overview: 1Q25 Pro Forma for Royalty Monetization 1) Includes public company warrants and shares; private warrants carried at zero value 2) Includes non-accruals; excludes warrants and equity. 3) As of May 2025 • Gross Finance Receivables: $321.9M • Gross Total Investment Assets

  13. Slide 13: Financial Snapshot

    11 Financial Snapshot 1) Eliminates provision for income taxes, MOD3 intangibles amortization, and non-cash mark-to-market changes on warrant assets and equity securities—see reconciliation on subsequent pages. $279.9 $280.3 $288.7 $292.7 $21.80 $22.43 $23.45 $23.94 2022 2023 2024 1Q25 SWK Stockhold

  14. Slide 14: Attractive Portfolio Yields

    12 Attractive Portfolio Yields SWK Targets Low-to-Mid Teens Effective Yields1 1Q25 Finance Segment Effective Yield was 14.5% 1) Effective yield is the rate at which income is expected to be recognized pursuant to the Company’s revenue recognition policies, if all payments are received pursuant to th

  15. Slide 15: Attractive Portfolio Yields: Realized vs. Effective Yield

    13.9% 14.2% 14.3% 13.9% 15.5% 14.5% 14.0% 14.4% 14.2% 14.6% 14.6% 15.5% 14.5% 22.5% 15.0% 17.5% 11.0% 15.3% 15.4% 14.7% 14.1% 15.2% 15.4% 13.8% 14.7% 15.5% 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25 Realized Yield vs. Effective Yield1 (at end of period) Effective Yield Realized

  16. Slide 16: Current Structured Credit Portfolio

    Current Structured Credit Portfolio Biotricity 12.27.2021 $12.0 million Structured Credit NeoLight 02.17.2023 $5.0 million Structured Credit 14 4WEB Medical 07.01.2021 $20.0 million Structured Credit eTon Pharmaceuticals 11.14.2019 $30.0 million Structured Credit Nicoya 10.13.2023 $6.0 million Struc

  17. Slide 17: Current Royalty Portfolio

    15 Current Royalty Portfolio Ideal Implant 04.27.2021 $5.0 million Reorg Synthetic Royalty Financing Best ABT 11.12.2018 $5.8 million Reorg Royalty Flowonix Medical 12.23.2020 $10.0 million Reorg Royalty Financing

  18. Slide 18: Portfolio Realizations Exit History

    16 Portfolio Realizations Exit History 12 Yrs. Exited Deals 44 Exits Cash Deployed $490M Cash Returned $701M MOIC 1.43x IRR 17.1% Figures reflective of SWKH balance sheet (i.e., excludes managed/partner transactions) ($s in Ms) Date Cash Investments # Security Invested Paid Off Invested Received MOI

  19. Slide 19: Exit Transactions: Targets, Buyers and Multiples

    ($ in M) Target Buyer Close Date Transaction TEV SWK Attachment Point1 LTV LTM Sales EV / LTM Sales Target Profitable Sale? Notes Nautilus Depomed Dec-13 48.7$ 22.5$ 46% 15.4$ 3.2x N Key asset was Cambia PDI Publicis Dec-15 25.0 20.0 80% 129.3 0.2x Y Tribute Aralez Feb-16 147.6 13.8 9% 26.5 5.6x N G

  20. Slide 20: SWK Sourcing

    18 SWK Sourcing • Cultivates and maintains a diverse array of longstanding, proprietary deal sources • Consistently sources over 100 actionable investment opportunities per year • Maintains disciplined “look-to-book” ratio of approximately 2-3% Intermediated 12% Hybrid 50% Proprietary 38% 2024 Total

  21. Slide 21: Slide JT0 See sma tables xls file in pitch deck folder JD Tamas, 2024-03-08T00:01:13.658

    Slide 18 JT0 See sma tables xls file in pitch deck folder JD Tamas, 2024-03-08T00:01:13.658

  22. Slide 22: Financing Structures

    Financing Structures 19 Product Acquisition • Primarily first lien, senior secured, floating rate loans • Typically include covenants, prepayment penalties, origination and exit fees, and warrant coverage • Provide working capital to support product commercialization and M&A Hybrid Financing Synthet

  23. Slide 23: Historical Financing: Narcan Royalty

    Historical Financing: Narcan Royalty 20 OPPORTUNITY SOLUTION • Opiant is a publicly-traded drug development company that receives a royalty on Narcan for developing the drug’s unique formulation – Novel formulation has a faster time to onset and more convenient and safer administration • Opiant need

  24. Slide 24: Historical Financing: Galil Medical

    Historical Financing: Galil Medical 21 OPPORTUNITY SOLUTION • In 2014, Galil was on the cusp of accelerating revenue growth, but was not yet cash-flow positive and could not tap traditional financing channels • Galil needed additional capital to run clinical trials and expand its sales force • In De

  25. Slide 25: MOD3 Pharma Corporate Overview

    22 MOD3 Pharma Corporate Overview CDMO Platform Revenue-generating CDMO platform Strategic Partnership • Revenue model: – Formulation and development work – Clinical trial material and drug manufacturing • Upgraded high potency manufacturing suite operational in 2021 • Focused on Phase I and Phase I

  26. Slide 26: Leadership Team

    23 Leadership Team Jody Staggs President and CEO • Joined in 2015 • Co-founded PBS Capital Management, predecessor to SWK • Prior to PBS, served as Senior Portfolio Analyst at Highland Capital Management • Investing experience in multiple asset classes Dr. Paul Shields MOD3 Pharma subsidiary CEO • J

  27. Slide 27: Why Invest in SWKH – Attractive Risk Reward Scenario

    Why Invest in SWKH – Attractive Risk Reward Scenario 24 Shareholder Return Focused • SWK story is not widely known, having uplisted to Nasdaq without benefit of traditional IPO • Analyst coverage and proactive investor relations effort have helped to increase SWK’s visibility • With a Book Value per

  28. Slide 28: Reconciliation of Non-GAAP Adjusted Net Income

    25 Reconciliation of Non-GAAP Adjusted Net Income  The following table provides a reconciliation of SWK's reported (GAAP) consolidated net income to SWK's adjusted consolidated net income (Non-GAAP) for the periods denoted in the table. The table eliminates provisions for income taxes, non-cash mar

  29. Slide 29: Reconciliation of Non-GAAP Specialty Finance Net Income

    26 Reconciliation of Non-GAAP Specialty Finance Net Income  The following table provides a reconciliation of SWK's consolidated adjusted income before provision for income taxes, listed in the table above, to the non-GAAP adjusted net income for the specialty finance business for the periods denote

  30. Slide 30: Contact Information

    27 Contact Information CONFIDENTIAL SWK Senior Management Investor & Media Relations: Alliance Advisors IR • Jody Staggs: ̶ Phone: 972.687.7252 ̶ Email: jstaggs@swkhold.com • Office address: 5956 Sherry Lane, Unit 650 Dallas, TX 75225 • Website: www.swkhold.com • Susan Xu: ̶ Phone: 778.323.0959 ̶ Em

  31. Slide 31: Collaborative Approach to Life Science Financing

    28 Collaborative Approach to Life Science Financing

SWK Holdings — Q1 2025 Earnings Presentation on 6ix